Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in cancer. The company’s news flow centers on the development of its lead program, silevertinib (also known as BDTX-1535), a brain-penetrant fourth-generation EGFR MasterKey inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
On this page, readers can follow company announcements related to clinical trial progress, including Phase 2 data updates in frontline NSCLC patients with non-classical EGFR mutations and investigator-sponsored studies in EGFR-altered GBM. Black Diamond’s releases describe objective response rates, CNS activity, duration of treatment or response, and plans for randomized Phase 2 trials in newly diagnosed GBM patients.
News items also cover corporate and financial updates, such as quarterly and annual financial results, cash runway commentary, and strategic priorities around advancing silevertinib. In addition, Black Diamond reports on business development activities, including a global licensing agreement with Servier for BDTX-4933, a Phase 1 therapy designed to target RAF/RAS-mutant solid tumors.
Investors and observers can use this news feed to track webcast and conference presentations, regulatory and development plans in NSCLC and GBM, and partnership discussions around pivotal development. Regular updates provide insight into how Black Diamond Therapeutics is progressing its MasterKey therapies across genetically defined tumor types and CNS-involved disease.
Black Diamond Therapeutics (BDTX) announced the submission of an IND for BDTX-1535, targeting EGFR mutations in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). The company will expand patient enrollment in the MasterKey-01 Phase 1 study for BDTX-189 to gather more data. Black Diamond aims to initiate IND-enabling studies for a CNS-penetrant BRAF program in 2022, while focusing resources on its pipeline and extending its cash runway into 2024. A clinical data update for BDTX-1535 is expected in the second half of 2023.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. The presentation will be available via a live webcast through the investor relations section of the company's website, with a replay accessible for 30 days after.
This Cambridge-based company focuses on developing MasterKey therapies targeting undrugged mutations in genetically defined cancers.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a company specializing in precision oncology, announced that CEO David M. Epstein, Ph.D., will present updates on the company's progress at two upcoming investor conferences. The first presentation is at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 4:40 PM ET. The second will be available on-demand at the Jefferies London Healthcare Conference starting November 18, 2021. Webcasts of the presentations will be accessible on the company's investor relations website.
Black Diamond Therapeutics reported financial results for Q3 2021, with cash reserves of $235 million. The company is preparing for the Phase 2 portion of the MasterKey-01 study for BDTX-189 and anticipates an IND filing for BDTX-1535 in H1 2022. Notable pre-clinical data for both programs were showcased at the ANE International Conference. R&D expenses rose to $27.6 million, while general and administrative expenses increased to $7.7 million, influenced by headcount growth and related costs.
Black Diamond Therapeutics (Nasdaq: BDTX) presented preclinical data for three early-stage pipeline programs at the AACR-NCI-EORTC Conference. The data highlights BDTX-1535's potential to address unmet needs in NSCLC patients with resistant mutations. This brain-penetrant inhibitor showed significant tumor growth inhibition in preclinical models and is on track for an IND filing in early 2022. The BRAF and FGFR programs also demonstrated innovative approaches targeting oncogenic mutations without the adverse effects seen with standard therapies, with IND filings anticipated in 2022.
Black Diamond Therapeutics (Nasdaq: BDTX) announced pre-clinical data presentation for three pipeline programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics scheduled from October 7-10, 2021. Notably, the oral presentation will highlight BDTX-1535, a CNS-penetrant inhibitor targeting resistant EGFR mutations, with potential implications for treating osimertinib-resistant non-small cell lung cancer. The company's innovative Mutation-Allostery-Pharmacology platform aims to discover therapies targeting oncogenic mutations in genetically defined cancers.
Black Diamond Therapeutics, a leader in precision oncology, announced its CEO, David M. Epstein, will present a corporate update at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 4:40 PM ET. This presentation is significant for shareholders and interested parties as it highlights the company's advancements in developing MasterKey therapies targeting undrugged mutations in genetically defined cancers. A live webcast will be available on their website with a replay accessible for three weeks.
Black Diamond Therapeutics and OpenEye Scientific have announced a strategic partnership aimed at enhancing drug discovery through the integration of OpenEye's Orion molecular design platform with Black Diamond's proprietary MAP drug discovery engine. This collaboration will facilitate rapid simulations and analysis of protein dynamics, accelerating the development of MasterKey inhibitors targeting oncogenic mutations. The partnership includes an upfront payment and future financial arrangements based on product success. This initiative highlights the integration of computational and genomic strategies in cancer therapeutics.
Black Diamond Therapeutics (BDTX) reported second-quarter results with a cash balance of $263.5 million as of June 30, 2021, aimed to sustain operations into 2023. The company is set to commence the Phase 2 trial of BDTX-189 in the latter half of 2021 following positive initial Phase 1 data, indicating tolerability and preliminary anti-cancer activity. Additionally, BDTX-1535 is on schedule for Investigational New Drug (IND) filing in 2022. The company also witnessed a rise in R&D expenses to $26.7 million due to increased operational activities.
Black Diamond Therapeutics (BDTX) announced the appointment of Mark A. Velleca, M.D., Ph.D., to its Board of Directors. With over 20 years of experience in biotechnology, particularly in oncology, Dr. Velleca previously served as CEO of G1 Therapeutics. He is expected to enhance the company's strategic direction in precision medicine for genetically defined cancers. The leadership change aims to strengthen Black Diamond’s capabilities in drug development as it continues advancing its MasterKey therapies targeting specific oncogenic mutations.